摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-Butyl-4-(5-furan-2-yl-2H-[1,2,4]triazol-3-yl)-1H-pyrazol-3-ylamine | 159979-90-5

中文名称
——
中文别名
——
英文名称
1-Butyl-4-(5-furan-2-yl-2H-[1,2,4]triazol-3-yl)-1H-pyrazol-3-ylamine
英文别名
1-butyl-4-[5-(furan-2-yl)-1H-1,2,4-triazol-3-yl]pyrazol-3-amine
1-Butyl-4-(5-furan-2-yl-2H-[1,2,4]triazol-3-yl)-1H-pyrazol-3-ylamine化学式
CAS
159979-90-5
化学式
C13H16N6O
mdl
——
分子量
272.31
InChiKey
GZSNICUIORTSQV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    20
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    98.6
  • 氢给体数:
    2
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    1-Butyl-4-(5-furan-2-yl-2H-[1,2,4]triazol-3-yl)-1H-pyrazol-3-ylamine对甲苯磺酸 作用下, 以 四氢呋喃N-甲基吡咯烷酮 为溶剂, 反应 22.0h, 生成 5-[[(4-methoxyphenyl)amino]carbonyl]amino-8-n-butyl-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
    参考文献:
    名称:
    吡唑并[4,3-e] 1,2,4-三唑并[1,5-c]嘧啶衍生物作为高效和选择性的人A(3)腺苷受体拮抗剂:在N(8)吡唑氮上链的影响。
    摘要:
    先前已经报道了以初步形式(Baraldi等人,J.Med.Chem.1999,42,4473-4478)作为高效和选择性的人A(3)腺苷受体拮抗剂的一系列吡唑并三唑并嘧啶类化合物。合成的化合物显示在亚纳摩尔范围内的A(3)腺苷受体亲和力和在人类A(1),A(2A),A(2B)和A(3)腺苷的放射性配体结合测定中评估的高水平选择性受体。特别是,分析了该链在N(8)吡唑氮上的作用。这项研究使我们能够鉴定出在N(8)吡唑具有甲基的衍生物与在N(5)位置具有4-甲氧基苯基氨基甲酰基部分的衍生物是在亲和力和选择性(hA)方面均具有最佳结合特性的化合物(3)= 0.2 nM,hA(1)/ hA(3)= 5485,hA(2A)/ hA(3)= 6950,hA(2B)/ hA(3)= 1305)。在特定功能模型中,所有化合物均被证明是完全拮抗剂,其中在稳定转染了人A(3)受体的CHO细胞膜中测量了IB-M
    DOI:
    10.1021/jm001047y
  • 作为产物:
    参考文献:
    名称:
    Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives:  Potent and Selective A2A Adenosine Antagonists
    摘要:
    A series of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives (10a-o,q,r), bearing alkyl and aralkyl chains on positions 7 and 8, were synthesized in the attempt to obtain potent and selective antagonists for the A(2A) adenosine receptor subtype. The compounds were tested in binding and functional assays to evaluate their potency for the A(2A) compared with the A(1) adenosine receptor subtype. In binding studies in rat brain membranes, most of the compounds showed affinity for A(2A) receptors in the low nanomolar range with a different degree of A(2A) versus A(1) selectivity. Comparison of N-7 (10a-d,h-o)- and N-8 (10e-g)-substituted pyrazolo derivatives indicates that N-7 substitution decreases the A(1) affinity with the concomitant increase of A(2A) selectivity. Specifically, the introduction of a 3-phenylpropyl group at pyrazolo nitrogen in position 7 (101) increased significantly the A(2A) selectivity, being 210-fold, while the A(2A) receptor affinity remained high (K-i = 2.4 nM). With regards to the affinity for A(2A) receptors, also the compound 10n, bearing in the 7-position a beta-morpholin-4-ylethyl group, deserves attention (K-i = 5.6 nM) even though the A(2A) selectivity (84-fold) was not as high as that of 101. Conversely, the compound 10m (N-7-4-phenylbutyl derivative) showed a remarkable selectivity (A(1)/A(2A) ratio = 129) associated with lower A(2A) affinity (K-i = 21 nM). In functional studies, most of the compounds examined reversed 5'-(N-ethylcarbamoyl)adenosine-induced inhibition of rabbit platelet aggregation inhibition which is a biological response mediated by the A(2A) receptor subtype. The compounds are potent and selective A(2A) antagonists which can be useful to elucidate the pathophysiological role of this adenosine receptor subtype. These compounds deserve to be further developed to assess their potential for treatment of neurodegenerative disorders such as Parkinson's disease.
    DOI:
    10.1021/jm950746l
点击查看最新优质反应信息

文献信息

  • Pyrazolo[4,3-<i>e</i>]-1,2,4-triazolo[1,5-<i>c</i>]pyrimidine Derivatives:  Potent and Selective A<sub>2A</sub> Adenosine Antagonists
    作者:Pier Giovanni Baraldi、Barbara Cacciari、Giampiero Spalluto、Maria José Pineda de las Infantas y Villatoro、Cristina Zocchi、Silvio Dionisotti、Ennio Ongini
    DOI:10.1021/jm950746l
    日期:1996.1.1
    A series of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives (10a-o,q,r), bearing alkyl and aralkyl chains on positions 7 and 8, were synthesized in the attempt to obtain potent and selective antagonists for the A(2A) adenosine receptor subtype. The compounds were tested in binding and functional assays to evaluate their potency for the A(2A) compared with the A(1) adenosine receptor subtype. In binding studies in rat brain membranes, most of the compounds showed affinity for A(2A) receptors in the low nanomolar range with a different degree of A(2A) versus A(1) selectivity. Comparison of N-7 (10a-d,h-o)- and N-8 (10e-g)-substituted pyrazolo derivatives indicates that N-7 substitution decreases the A(1) affinity with the concomitant increase of A(2A) selectivity. Specifically, the introduction of a 3-phenylpropyl group at pyrazolo nitrogen in position 7 (101) increased significantly the A(2A) selectivity, being 210-fold, while the A(2A) receptor affinity remained high (K-i = 2.4 nM). With regards to the affinity for A(2A) receptors, also the compound 10n, bearing in the 7-position a beta-morpholin-4-ylethyl group, deserves attention (K-i = 5.6 nM) even though the A(2A) selectivity (84-fold) was not as high as that of 101. Conversely, the compound 10m (N-7-4-phenylbutyl derivative) showed a remarkable selectivity (A(1)/A(2A) ratio = 129) associated with lower A(2A) affinity (K-i = 21 nM). In functional studies, most of the compounds examined reversed 5'-(N-ethylcarbamoyl)adenosine-induced inhibition of rabbit platelet aggregation inhibition which is a biological response mediated by the A(2A) receptor subtype. The compounds are potent and selective A(2A) antagonists which can be useful to elucidate the pathophysiological role of this adenosine receptor subtype. These compounds deserve to be further developed to assess their potential for treatment of neurodegenerative disorders such as Parkinson's disease.
  • Pyrazolo[4,3-<i>e</i>]1,2,4-triazolo[1,5-<i>c</i>]pyrimidine Derivatives as Highly Potent and Selective Human A<sub>3</sub> Adenosine Receptor Antagonists:  Influence of the Chain at the N<sup>8</sup> Pyrazole Nitrogen
    作者:Pier Giovanni Baraldi、Barbara Cacciari、Romeo Romagnoli、Giampiero Spalluto、Stefano Moro、Karl-Norbert Klotz、Edward Leung、Katia Varani、Stefania Gessi、Stefania Merighi、Pier Andrea Borea
    DOI:10.1021/jm001047y
    日期:2000.12.1
    IB-MECA was measured in membranes of CHO cells stably transfected with the human A(3) receptor. The new compounds are among the most potent and selective A(3) antagonists so far described. The derivatives with higher affinity at human A(3) adenosine receptors proved to be antagonists, in the cAMP assay, capable of inhibiting the effect of IB-MECA with IC(50) values in the nanomolar range, with a trend strictly
    先前已经报道了以初步形式(Baraldi等人,J.Med.Chem.1999,42,4473-4478)作为高效和选择性的人A(3)腺苷受体拮抗剂的一系列吡唑并三唑并嘧啶类化合物。合成的化合物显示在亚纳摩尔范围内的A(3)腺苷受体亲和力和在人类A(1),A(2A),A(2B)和A(3)腺苷的放射性配体结合测定中评估的高水平选择性受体。特别是,分析了该链在N(8)吡唑氮上的作用。这项研究使我们能够鉴定出在N(8)吡唑具有甲基的衍生物与在N(5)位置具有4-甲氧基苯基氨基甲酰基部分的衍生物是在亲和力和选择性(hA)方面均具有最佳结合特性的化合物(3)= 0.2 nM,hA(1)/ hA(3)= 5485,hA(2A)/ hA(3)= 6950,hA(2B)/ hA(3)= 1305)。在特定功能模型中,所有化合物均被证明是完全拮抗剂,其中在稳定转染了人A(3)受体的CHO细胞膜中测量了IB-M
查看更多

同类化合物

辛基羟乙基咪唑啉 辛基羟乙基咪唑啉 肉豆蔻基羟乙基咪唑啉 甲基-(1-甲基-吡咯烷-2-亚基)-胺 甲基(5-甲基-1,2-恶唑-3-基)氨基甲酸酯 油基胺乙基咪唑啉 氯代醋酸钠与4,5-二氢-十一烷基-1H-咪唑-1-乙醇和氢氧化钠的反应产物 月桂基羟乙基咪唑啉 恶唑-4-基氨基甲酸叔丁酯 异硬脂基羟乙基咪唑啉 异噁隆 异丙基亚氨基吡咯烷 噻唑-2,4-二胺 噁唑-4-胺 叔-丁基2-氨基-6,7-二氢吡唑并[1,5-A]吡嗪-5(4H)-甲酸基酯 十七碳-2-烯基-4,5-二氢-1H-咪唑-1-乙醇盐酸盐 偶氮引发剂VA-064 依凡达明 二氨基吡唑 乙基3-(乙基氨基)-5-甲基-1,2-恶唑-4-羧酸酯 alpha-(氯甲基)-2-异丙基-5-硝基-2H-咪唑-2-乙醇 alpha,4,4-三甲基-2-十一烷基-2-咪唑啉-1-乙醇 Z-2-(8-十七烯基)-4,5-二氢-1H-咪唑-1-乙醇 N-甲基-3-氨基吡唑 N-甲基-2-吡咯烷酮肟 N-甲基-1,2-噻唑-3-胺1,1-二氧化物 N-环己基-1,2-噻唑-3-胺1,1-二氧化物 N-叔-丁基-5-甲基-2H-吡唑-3-胺 N-乙基-N-(5-甲基-3-异恶唑基)-乙酰胺 N-乙基-1,2-噻唑-3-胺1,1-二氧化物 N-乙基-1,2,5-恶二唑-3,4-二胺 N-[2-[2-[(E)-十七碳-8-烯基]-4,5-二氢咪唑-1-基]乙基]乙烷-1,2-二胺 N-[2-[2-(13-二十一碳烯-1-基)-4,5-二氢-1H-咪唑-1-基]乙基]乙二胺 N-[2-(4,5-二氢-2-十九烷基-1H-咪唑-1-基)乙基]乙二胺 N-[2-(4,5-二氢-2-十一烷基-1H-咪唑-1-基)乙基]乙二胺 N-[(2Z)-哌嗪-2-亚基]-2,2,2-三氟乙酰肼 N-[(2-甲基苯基)氨基甲硫杂酰]-2-(4-羰基-2-苯基喹唑啉-3(4H)-基)-3-苯基丙酰胺 N-BOC-4-氨基噻唑 N-3-异恶唑氨基甲酸叔丁酯 N-(噻二唑-4-基)氨基甲酸乙酯 N-(5-叔丁基-1H-吡唑-3-基)氨基甲酸甲酯 N-(4,5-二甲基-3-异噁唑)氨基甲酸1,1-二甲基乙酯 N-(2-氨基乙基)-N'-[2-[2-(13-二十一碳烯基)-4,5-二氢-1H-咪唑-1-基]乙基]乙二胺 N-(2-氨基乙基)-N'-[2-(4,5-二氢-2-十九烷基-1H-咪唑-1-基)乙基]乙二胺 N-(2-氨基乙基)-N'-[2-(2-十七烷基-4,5-二氢-1H-咪唑-1-基)乙基]乙二胺 N,N,N',N'-四甲基-4,6-二(三甲基硅烷基)环戊二烯并[c]吡咯-1,3-二胺 N,N,N',N',5-戊甲基环戊并[c]吡咯-1,3-二胺 N,N,3,3-四甲基氮杂环丙烯-2-胺 N,5-二甲基-1,2-恶唑-3-胺 6H-吡唑并[1,5-c][1,2,3]三唑-3,5,6-三胺